Expression ||| S:0 E:10 ||| NN
,  ||| S:10 E:12 ||| ,
Clinical  ||| S:12 E:21 ||| NNP
Significance ||| S:21 E:33 ||| NNP
,  ||| S:33 E:35 ||| ,
and  ||| S:35 E:39 ||| CC
Receptor  ||| S:39 E:48 ||| NNP
Identification  ||| S:48 E:63 ||| NNP
of  ||| S:63 E:66 ||| IN
the  ||| S:66 E:70 ||| DT
Newest  ||| S:70 E:77 ||| NNP
B7  ||| S:77 E:80 ||| NNP
Family  ||| S:80 E:87 ||| NNP
Member  ||| S:87 E:94 ||| NNP
HHLA2  ||| S:94 E:100 ||| NNP
Protein  ||| S:100 E:108 ||| NNP
HHLA2  ||| S:108 E:114 ||| NNP
( ||| S:114 E:115 ||| -LRB-
B7H7 ||| S:115 E:119 ||| CD
/ ||| S:119 E:120 ||| CD
B7-H5 ||| S:120 E:125 ||| CD
/ ||| S:125 E:126 ||| CD
B7y ||| S:126 E:129 ||| CD
)  ||| S:129 E:131 ||| -RRB-
is  ||| S:131 E:134 ||| VBZ
a  ||| S:134 E:136 ||| DT
newly  ||| S:136 E:142 ||| RB
identified  ||| S:142 E:153 ||| VBN
B7  ||| S:153 E:156 ||| CD
family  ||| S:156 E:163 ||| NN
member  ||| S:163 E:170 ||| NN
that  ||| S:170 E:175 ||| WDT
regulates  ||| S:175 E:185 ||| VBZ
human  ||| S:185 E:191 ||| JJ
T-cell  ||| S:191 E:198 ||| JJ
functions ||| S:198 E:207 ||| NNS
.  ||| S:207 E:209 ||| .
However ||| S:209 E:216 ||| RB
,  ||| S:216 E:218 ||| ,
its  ||| S:218 E:222 ||| PRP$
protein  ||| S:222 E:230 ||| NN
expression  ||| S:230 E:241 ||| NN
in  ||| S:241 E:244 ||| IN
human  ||| S:244 E:250 ||| JJ
organs  ||| S:250 E:257 ||| NNS
and  ||| S:257 E:261 ||| CC
significance  ||| S:261 E:274 ||| NN
in  ||| S:274 E:277 ||| IN
human  ||| S:277 E:283 ||| JJ
diseases  ||| S:283 E:292 ||| NNS
are  ||| S:292 E:296 ||| VBP
unknown ||| S:296 E:303 ||| JJ
.  ||| S:303 E:305 ||| .
The  ||| S:305 E:309 ||| DT
objective  ||| S:309 E:319 ||| NN
of  ||| S:319 E:322 ||| IN
this  ||| S:322 E:327 ||| DT
study  ||| S:327 E:333 ||| NN
was  ||| S:333 E:337 ||| VBD
to  ||| S:337 E:340 ||| TO
analyze  ||| S:340 E:348 ||| VB
HHLA2  ||| S:348 E:354 ||| CD
protein  ||| S:354 E:362 ||| NN
expression  ||| S:362 E:373 ||| NN
in  ||| S:373 E:376 ||| IN
normal  ||| S:376 E:383 ||| JJ
human  ||| S:383 E:389 ||| JJ
tissues  ||| S:389 E:397 ||| NNS
and  ||| S:397 E:401 ||| CC
cancers ||| S:401 E:408 ||| NNS
,  ||| S:408 E:410 ||| ,
as  ||| S:410 E:413 ||| RB
well  ||| S:413 E:418 ||| RB
as  ||| S:418 E:421 ||| IN
its  ||| S:421 E:425 ||| PRP$
prognostic  ||| S:425 E:436 ||| JJ
significance ||| S:436 E:448 ||| NN
,  ||| S:448 E:450 ||| ,
to  ||| S:450 E:453 ||| TO
explore  ||| S:453 E:461 ||| VB
mechanisms  ||| S:461 E:472 ||| NNS
regulating  ||| S:472 E:483 ||| VBG
HHLA2  ||| S:483 E:489 ||| CD
expression ||| S:489 E:499 ||| NN
,  ||| S:499 E:501 ||| ,
and  ||| S:501 E:505 ||| CC
to  ||| S:505 E:508 ||| TO
identify  ||| S:508 E:517 ||| VB
candidate  ||| S:517 E:527 ||| NN
HHLA2  ||| S:527 E:533 ||| CD
receptors ||| S:533 E:542 ||| NNS
.  ||| S:542 E:544 ||| .
An  ||| S:544 E:547 ||| DT
immunohistochemistry  ||| S:547 E:568 ||| JJ
protocol  ||| S:568 E:577 ||| NN
and  ||| S:577 E:581 ||| CC
a  ||| S:581 E:583 ||| DT
flow  ||| S:583 E:588 ||| NN
cytometry  ||| S:588 E:598 ||| NN
assay  ||| S:598 E:604 ||| NN
with  ||| S:604 E:609 ||| IN
newly  ||| S:609 E:615 ||| RB
generated  ||| S:615 E:625 ||| VBN
monoclonal  ||| S:625 E:636 ||| JJ
antibodies  ||| S:636 E:647 ||| NNS
were  ||| S:647 E:652 ||| VBD
developed  ||| S:652 E:662 ||| VBN
to  ||| S:662 E:665 ||| TO
examine  ||| S:665 E:673 ||| VB
HHLA2  ||| S:673 E:679 ||| CD
protein ||| S:679 E:686 ||| NN
.  ||| S:686 E:688 ||| .
HHLA2  ||| S:688 E:694 ||| NNP
gene  ||| S:694 E:699 ||| NN
copy-number  ||| S:699 E:711 ||| JJ
variation  ||| S:711 E:721 ||| NN
was  ||| S:721 E:725 ||| VBD
analyzed  ||| S:725 E:734 ||| VBN
from  ||| S:734 E:739 ||| IN
cancer  ||| S:739 E:746 ||| NN
genomic  ||| S:746 E:754 ||| NN
data ||| S:754 E:758 ||| NNS
.  ||| S:758 E:760 ||| .
The  ||| S:760 E:764 ||| DT
combination  ||| S:764 E:776 ||| NN
of  ||| S:776 E:779 ||| IN
bioinformatics  ||| S:779 E:794 ||| JJ
analysis  ||| S:794 E:803 ||| NN
and  ||| S:803 E:807 ||| CC
immunologic  ||| S:807 E:819 ||| JJ
approaches  ||| S:819 E:830 ||| NNS
was  ||| S:830 E:834 ||| VBD
established  ||| S:834 E:846 ||| VBN
to  ||| S:846 E:849 ||| TO
explore  ||| S:849 E:857 ||| VB
HHLA2  ||| S:857 E:863 ||| CD
receptors ||| S:863 E:872 ||| NNS
.  ||| S:872 E:874 ||| .
HHLA2  ||| S:874 E:880 ||| NNP
protein  ||| S:880 E:888 ||| NN
was  ||| S:888 E:892 ||| VBD
detected  ||| S:892 E:901 ||| VBN
in  ||| S:901 E:904 ||| IN
trophoblastic  ||| S:904 E:918 ||| JJ
cells  ||| S:918 E:924 ||| NNS
of  ||| S:924 E:927 ||| IN
the  ||| S:927 E:931 ||| DT
placenta  ||| S:931 E:940 ||| NN
and  ||| S:940 E:944 ||| CC
the  ||| S:944 E:948 ||| DT
epithelium  ||| S:948 E:959 ||| NN
of  ||| S:959 E:962 ||| IN
gut ||| S:962 E:965 ||| NN
,  ||| S:965 E:967 ||| ,
kidney ||| S:967 E:973 ||| NN
,  ||| S:973 E:975 ||| ,
gallbladder ||| S:975 E:986 ||| NN
,  ||| S:986 E:988 ||| ,
and  ||| S:988 E:992 ||| CC
breast ||| S:992 E:998 ||| NN
,  ||| S:998 E:1000 ||| ,
but  ||| S:1000 E:1004 ||| CC
not  ||| S:1004 E:1008 ||| RB
in  ||| S:1008 E:1011 ||| IN
most  ||| S:1011 E:1016 ||| RBS
other  ||| S:1016 E:1022 ||| JJ
organs ||| S:1022 E:1028 ||| NNS
.  ||| S:1028 E:1030 ||| .
In  ||| S:1030 E:1033 ||| IN
contrast ||| S:1033 E:1041 ||| NN
,  ||| S:1041 E:1043 ||| ,
HHLA2  ||| S:1043 E:1049 ||| CD
protein  ||| S:1049 E:1057 ||| NN
was  ||| S:1057 E:1061 ||| VBD
widely  ||| S:1061 E:1068 ||| RB
expressed  ||| S:1068 E:1078 ||| VBN
in  ||| S:1078 E:1081 ||| IN
human  ||| S:1081 E:1087 ||| JJ
cancers  ||| S:1087 E:1095 ||| NNS
from  ||| S:1095 E:1100 ||| IN
the  ||| S:1100 E:1104 ||| DT
breast ||| S:1104 E:1110 ||| NN
,  ||| S:1110 E:1112 ||| ,
lung ||| S:1112 E:1116 ||| NN
,  ||| S:1116 E:1118 ||| ,
thyroid ||| S:1118 E:1125 ||| NN
,  ||| S:1125 E:1127 ||| ,
melanoma ||| S:1127 E:1135 ||| NN
,  ||| S:1135 E:1137 ||| ,
pancreas ||| S:1137 E:1145 ||| NN
,  ||| S:1145 E:1147 ||| ,
ovary ||| S:1147 E:1152 ||| NN
,  ||| S:1152 E:1154 ||| ,
liver ||| S:1154 E:1159 ||| NN
,  ||| S:1159 E:1161 ||| ,
bladder ||| S:1161 E:1168 ||| NN
,  ||| S:1168 E:1170 ||| ,
colon ||| S:1170 E:1175 ||| NN
,  ||| S:1175 E:1177 ||| ,
prostate ||| S:1177 E:1185 ||| NN
,  ||| S:1185 E:1187 ||| ,
kidney ||| S:1187 E:1193 ||| NN
,  ||| S:1193 E:1195 ||| ,
and  ||| S:1195 E:1199 ||| CC
esophagus ||| S:1199 E:1208 ||| NN
.  ||| S:1208 E:1210 ||| .
In  ||| S:1210 E:1213 ||| IN
a  ||| S:1213 E:1215 ||| DT
cohort  ||| S:1215 E:1222 ||| NN
of  ||| S:1222 E:1225 ||| IN
50  ||| S:1225 E:1228 ||| CD
patients  ||| S:1228 E:1237 ||| NNS
with  ||| S:1237 E:1242 ||| IN
stage  ||| S:1242 E:1248 ||| NN
I-III  ||| S:1248 E:1254 ||| JJ
triple-negative  ||| S:1254 E:1270 ||| JJ
breast  ||| S:1270 E:1277 ||| NN
cancer ||| S:1277 E:1283 ||| NN
,  ||| S:1283 E:1285 ||| ,
56 ||| S:1285 E:1287 ||| CD
%  ||| S:1287 E:1289 ||| NN
of  ||| S:1289 E:1292 ||| IN
patients  ||| S:1292 E:1301 ||| NNS
had  ||| S:1301 E:1305 ||| VBD
aberrant  ||| S:1305 E:1314 ||| JJ
expression  ||| S:1314 E:1325 ||| NN
of  ||| S:1325 E:1328 ||| IN
HHLA2  ||| S:1328 E:1334 ||| CD
on  ||| S:1334 E:1337 ||| IN
their  ||| S:1337 E:1343 ||| PRP$
tumors ||| S:1343 E:1349 ||| NNS
,  ||| S:1349 E:1351 ||| ,
and  ||| S:1351 E:1355 ||| CC
high  ||| S:1355 E:1360 ||| JJ
HHLA2  ||| S:1360 E:1366 ||| CD
expression  ||| S:1366 E:1377 ||| NN
was  ||| S:1377 E:1381 ||| VBD
significantly  ||| S:1381 E:1395 ||| RB
associated  ||| S:1395 E:1406 ||| VBN
with  ||| S:1406 E:1411 ||| IN
regional  ||| S:1411 E:1420 ||| JJ
lymph  ||| S:1420 E:1426 ||| JJ
node  ||| S:1426 E:1431 ||| JJ
metastasis  ||| S:1431 E:1442 ||| NN
and  ||| S:1442 E:1446 ||| CC
stage ||| S:1446 E:1451 ||| NN
.  ||| S:1451 E:1453 ||| .
The  ||| S:1453 E:1457 ||| DT
Cancer  ||| S:1457 E:1464 ||| NNP
Genome  ||| S:1464 E:1471 ||| NNP
Atlas  ||| S:1471 E:1477 ||| NNP
revealed  ||| S:1477 E:1486 ||| VBD
that  ||| S:1486 E:1491 ||| IN
HHLA2  ||| S:1491 E:1497 ||| CD
copy-number  ||| S:1497 E:1509 ||| JJ
gains  ||| S:1509 E:1515 ||| NNS
were  ||| S:1515 E:1520 ||| VBD
present  ||| S:1520 E:1528 ||| JJ
in  ||| S:1528 E:1531 ||| IN
29 ||| S:1531 E:1533 ||| CD
%  ||| S:1533 E:1535 ||| NN
of  ||| S:1535 E:1538 ||| IN
basal  ||| S:1538 E:1544 ||| JJ
breast  ||| S:1544 E:1551 ||| NN
cancers ||| S:1551 E:1558 ||| NNS
,  ||| S:1558 E:1560 ||| ,
providing  ||| S:1560 E:1570 ||| VBG
a  ||| S:1570 E:1572 ||| DT
potential  ||| S:1572 E:1582 ||| JJ
mechanism  ||| S:1582 E:1592 ||| NN
for  ||| S:1592 E:1596 ||| IN
increased  ||| S:1596 E:1606 ||| JJ
HHLA2  ||| S:1606 E:1612 ||| CD
protein  ||| S:1612 E:1620 ||| NN
expression  ||| S:1620 E:1631 ||| NN
in  ||| S:1631 E:1634 ||| IN
breast  ||| S:1634 E:1641 ||| JJ
cancer ||| S:1641 E:1647 ||| NN
.  ||| S:1647 E:1649 ||| .
Finally ||| S:1649 E:1656 ||| RB
,  ||| S:1656 E:1658 ||| ,
Transmembrane  ||| S:1658 E:1672 ||| NNP
and  ||| S:1672 E:1676 ||| CC
Immunoglobulin  ||| S:1676 E:1691 ||| NNP
Domain  ||| S:1691 E:1698 ||| NNP
Containing  ||| S:1698 E:1709 ||| NNP
2  ||| S:1709 E:1711 ||| CD
( ||| S:1711 E:1712 ||| -LRB-
TMIGD2 ||| S:1712 E:1718 ||| NNP
)  ||| S:1718 E:1720 ||| -RRB-
was  ||| S:1720 E:1724 ||| VBD
identified  ||| S:1724 E:1735 ||| VBN
as  ||| S:1735 E:1738 ||| IN
one  ||| S:1738 E:1742 ||| CD
of  ||| S:1742 E:1745 ||| IN
the  ||| S:1745 E:1749 ||| DT
receptors  ||| S:1749 E:1759 ||| NN
for  ||| S:1759 E:1763 ||| IN
HHLA2 ||| S:1763 E:1768 ||| CD
.  ||| S:1768 E:1770 ||| .
Wide  ||| S:1770 E:1775 ||| JJ
expression  ||| S:1775 E:1786 ||| NN
of  ||| S:1786 E:1789 ||| IN
HHLA2  ||| S:1789 E:1795 ||| CD
in  ||| S:1795 E:1798 ||| IN
human  ||| S:1798 E:1804 ||| JJ
malignancies ||| S:1804 E:1816 ||| NN
,  ||| S:1816 E:1818 ||| ,
together  ||| S:1818 E:1827 ||| RB
with  ||| S:1827 E:1832 ||| IN
its  ||| S:1832 E:1836 ||| PRP$
association  ||| S:1836 E:1848 ||| NN
with  ||| S:1848 E:1853 ||| IN
poor  ||| S:1853 E:1858 ||| JJ
prognostic  ||| S:1858 E:1869 ||| JJ
factors  ||| S:1869 E:1877 ||| NNS
and  ||| S:1877 E:1881 ||| CC
its  ||| S:1881 E:1885 ||| PRP$
T-cell  ||| S:1885 E:1892 ||| JJ
coinhibitory  ||| S:1892 E:1905 ||| JJ
capability ||| S:1905 E:1915 ||| NN
,  ||| S:1915 E:1917 ||| ,
suggests  ||| S:1917 E:1926 ||| VBZ
that  ||| S:1926 E:1931 ||| IN
the  ||| S:1931 E:1935 ||| DT
HHLA2  ||| S:1935 E:1941 ||| JJ
pathway  ||| S:1941 E:1949 ||| NN
represents  ||| S:1949 E:1960 ||| VBZ
a  ||| S:1960 E:1962 ||| DT
novel  ||| S:1962 E:1968 ||| NN
immunosuppressive  ||| S:1968 E:1986 ||| NN
mechanism  ||| S:1986 E:1996 ||| NN
within  ||| S:1996 E:2003 ||| IN
the  ||| S:2003 E:2007 ||| DT
tumor  ||| S:2007 E:2013 ||| NN
microenvironment  ||| S:2013 E:2030 ||| NNS
and  ||| S:2030 E:2034 ||| CC
an  ||| S:2034 E:2037 ||| DT
attractive  ||| S:2037 E:2048 ||| JJ
target  ||| S:2048 E:2055 ||| NN
for  ||| S:2055 E:2059 ||| IN
human  ||| S:2059 E:2065 ||| JJ
cancer  ||| S:2065 E:2072 ||| NN
therapy ||| S:2072 E:2079 ||| NN
.  ||| S:2079 E:2081 ||| .
